Paratek Pharmaceuticals Inc. (NASDAQ:PRTK)‘s stock had its “outperform” rating reiterated by research analysts at Robert W. Baird in a note issued to investors on Sunday. They currently have a $40.00 target price on the specialty pharmaceutical company’s stock. Robert W. Baird’s target price suggests a potential upside of 210.08% from the stock’s previous close.

Several other analysts have also recently issued reports on the company. Zacks Investment Research cut Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 6th. Guggenheim reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Tuesday, August 16th. Leerink Swann reaffirmed a “buy” rating and set a $23.00 price objective on shares of Paratek Pharmaceuticals in a research report on Thursday, November 3rd. HC Wainwright reaffirmed a “buy” rating on shares of Paratek Pharmaceuticals in a research report on Tuesday, August 16th. Finally, Cantor Fitzgerald set a $28.00 price objective on Paratek Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, November 2nd. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $33.57.

Analyst Recommendations for Paratek Pharmaceuticals (NASDAQ:PRTK)

Paratek Pharmaceuticals (NASDAQ:PRTK) traded down 0.77% during trading on Friday, hitting $12.90. The stock had a trading volume of 85,136 shares. The stock’s 50-day moving average price is $12.35 and its 200-day moving average price is $13.44. Paratek Pharmaceuticals has a 1-year low of $9.80 and a 1-year high of $22.00. The company’s market capitalization is $291.89 million.

Paratek Pharmaceuticals (NASDAQ:PRTK) last posted its earnings results on Wednesday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.38) by $0.34.

Institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN raised its position in Paratek Pharmaceuticals by 196.5% in the third quarter. Wells Fargo & Company MN now owns 8,005 shares of the specialty pharmaceutical company’s stock valued at $104,000 after buying an additional 5,305 shares during the last quarter. American International Group Inc. raised its position in Paratek Pharmaceuticals by 16.2% in the second quarter. American International Group Inc. now owns 8,297 shares of the specialty pharmaceutical company’s stock valued at $115,000 after buying an additional 1,156 shares during the last quarter. Nationwide Fund Advisors raised its position in Paratek Pharmaceuticals by 7.5% in the second quarter. Nationwide Fund Advisors now owns 8,924 shares of the specialty pharmaceutical company’s stock valued at $124,000 after buying an additional 621 shares during the last quarter. BlackRock Advisors LLC raised its position in Paratek Pharmaceuticals by 86.5% in the third quarter. BlackRock Advisors LLC now owns 9,802 shares of the specialty pharmaceutical company’s stock valued at $128,000 after buying an additional 4,545 shares during the last quarter. Finally, Ardsley Advisory Partners acquired a new position in Paratek Pharmaceuticals during the third quarter valued at about $130,000. Hedge funds and other institutional investors own 78.99% of the company’s stock.

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc (Paratek), formerly Transcept Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Paratek’s antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI).

5 Day Chart for NASDAQ:PRTK

Receive News & Stock Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.